Publication at Faculty of Medicine in Hradec Králové |
2013
Abstract
Oral antidiabetic agent pioglitazone is PPARgama agonist. Its main effects are higher insulin sensitivity and HDL cholesterol, lower hyperglycemia and triglycerides.
The risk of hypoglycemia is very low, caution is necessary in the diabetics with chronic cardial insuuficiency (weight gain, retention of fluids), with osteoporosis (risk of fratures). Pioglitazone is contraindicated in the patients with bladder carcinoma or unclear microscopic hematuria.
It is very effective oral antidiabetic agent in type 2 diabetics in monotherapy and in the combination with all other antidiabetics, including insulin.